Letrozol Ratiopharm

Letrozole, the active ingredient in Letrozol Ratiopharm, is a selective, non‑steroidal aromatase inhibitor presented as an oral tablet for oral administration. It reduces estrogen production and is indicated for hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozole is used in the management of estrogen‑dependent breast cancer.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces risk of disease recurrence and progression. - Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer: decreases likelihood of relapse after surgery. - Metastatic hormone receptor‑positive breast cancer: helps control tumor growth and prolongs survival.

Letrozole may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of intense warmth. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Osteoporosis or severe bone loss: increased fracture risk. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Liver function abnormalities: elevated transaminases. - Interstitial lung disease: rare pulmonary inflammation. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Cardiac QT prolongation: potential arrhythmia risk.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor bone health: assess bone mineral density and consider calcium/vitamin D supplementation. - Evaluate liver function: perform baseline and periodic liver enzyme tests. - Assess cardiovascular risk: watch for signs of thrombosis or embolism. - Use caution in severe renal impairment: adjust monitoring as needed. - Contraindicated in pregnancy: avoid use in women of childbearing potential. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Letrozole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Tamoxifen: antagonistic effect reduces therapeutic benefit. - Estrogen replacement therapy: counters aromatase inhibition. - Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring closer monitoring. - NSAIDs: may increase gastrointestinal bleeding risk when combined with letrozole.